Upgrade to SI Premium - Free Trial

BioAge Labs (BIOA)

5.51 -0.05 (0.90%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target October 14, 2026 8:00 AM - Globe NewsWire UBS Starts BioAge Labs Inc (BIOA) at Neutral October 12, 2026 2:23 AM - StreetInsider Form 8-K BioAge Labs, Inc. For: Oct 02 October 2, 2026 4:15 PM - SEC Filing BioAge Labs to Present at Upcoming Investor Conferences September 25, 2026 4:30 PM - Globe NewsWire First patient treated with Leqembi® (lecanemab) in Sweden September 22, 2026 10:40 AM - PR NewsWire Japan approves subcutaneous autoinjector form of Leqembi for Alzheimer's September 16, 2026 2:23 AM - StreetInsider Leqembi® Pen subcutaneous formulation approved in Japan September 16, 2026 2:15 AM - PR NewsWire Leqembi Iqlik® for initiation treatment launched in the US August 24, 2026 8:40 AM - PR NewsWire BioArctic and Mesenkia enter oncology research collaboration August 19, 2026 5:43 AM - PR NewsWire Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST August 19, 2026 2:55 AM - PR NewsWire Form SCHEDULE 13G/A BioAge Labs, Inc. Filed by: Cormorant Asset Management, LP August 14, 2026 2:01 PM - SEC Filing BioAmber (BIOA) Reports Q2 Loss of $0.58 August 5, 2026 6:21 PM - StreetInsider Form 10-Q BioAge Labs, Inc. For: Jun 30 August 5, 2026 5:01 PM - SEC Filing Form 8-K BioAge Labs, Inc. For: Aug 05 August 5, 2026 4:55 PM - SEC Filing BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates August 5, 2026 4:50 PM - Globe NewsWire BioAge Labs Inc (BIOA) PT Lowered to $21 at Jefferies July 31, 2026 1:10 PM - StreetInsider Monte Rose, BioAge Labs Crushed Following NVO Results July 31, 2026 7:40 AM - StreetInsider Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026 July 29, 2026 6:28 AM - PR NewsWire Full Article List